TABLE 1.
Baseline demographics and disease characteristics in patients ≥50 years of age (full analysis set)
| Eptinezumab 100 mg (n = 132) | Eptinezumab 300 mg (n = 127) | Placebo (n = 126) | |
|---|---|---|---|
| Age (years), mean (SD) | 55.9 (4.37) | 55.7 (4.93) | 55.5 (4.91) |
| Sex: Female, n (%) | 111 (84.1%) | 115 (90.6%) | 110 (87.3%) |
| Race, n (%) | |||
| White | 124 (93.9%) | 121 (95.3%) | 115 (91.3%) |
| Black | 5 (3.8%) | 4 (3.1%) | 8 (6.3%) |
| Other | 3 (2.3%) | 2 (1.6%) | 3 (2.4%) |
| Body mass index (kg/m2), mean (SD) | 27.5 (4.79) | 26.5 (5.18) | 28.0 (6.52) |
| Age at migraine diagnosis (years), mean (SD) | 28.4 (12.93) | 26.3 (10.97) | 28.0 (12.01) |
| Duration of migraine diagnosis (years), mean (SD) | 27.5 (13.65) | 29.4 (11.79) | 27.6 (12.86) |
| Duration of chronic migraines (years), mean (SD) | 17.3 (16.03) | 19.7 (15.29) | 16.9 (14.85) |
| Baseline migraine days, mean (SD) | 13.5 (5.06) | 12.9 (5.42) | 12.7 (5.30) |
| Baseline headache days, mean (SD) | 16.9 (5.59) | 16.2 (5.69) | 16.1 (5.95) |
| Diagnosis, n (%) | |||
| Episodic migraine | 42 (31.8%) | 52 (40.9%) | 49 (38.9%) |
| Chronic migraine | 90 (68.2%) | 75 (59.1%) | 77 (61.1%) |
| Chronic migraine and MOH a | 34 (25.8%) | 35 (27.6%) | 31 (24.6%) |
| Baseline medication use in ≥10% of patients, n (%) | |||
| Sumatriptan | 41 (31.1%) | 49 (38.6%) | 63 (50.0%) |
| Ibuprofen | 38 (28.8%) | 41 (32.3%) | 35 (27.8%) |
| Acetylsalicylic acid+paracetamol+caffeine | 38 (28.8%) | 36 (28.3%) | 32 (25.4%) |
| Paracetamol | 20 (15.2%) | 19 (15.0%) | 14 (11.1%) |
| Rizatriptan | 21 (15.9%) | 15 (11.8%) | 14 (11.1%) |
| Topiramate | 8 (6.1%) | 13 (10.2%) | 14 (11.1%) |
| Vitamins NOS | 10 (7.6%) | 13 (10.2%) | 10 (7.9%) |
| Baseline preventive or acute medication use, n (%) | |||
| Preventive | 46 (34.8%) | 39 (30.7%) | 42 (33.3%) |
| Acute | 126 (95.5%) | 127 (100.0%) | 122 (96.8%) |
a
Patients in PROMISE‐2 (chronic migraine) were allowed to have a secondary diagnosis of MOH at enrollment. 30 MOH, medication overuse headache; NOS, not otherwise specified; and SD, standard deviation.